These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 10547558)

  • 1. Antiapoptotic Bcl-2 family protein expression increases with progression of oligodendroglioma.
    Deininger MH; Weller M; Streffer J; Meyermann R
    Cancer; 1999 Nov; 86(9):1832-9. PubMed ID: 10547558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of Bcl-2 and Bax in oligodendrogliomas and their relationship to apoptosis.
    Delgado MB; Anderson JR; Whittle IR; Wharton SB
    Neuropathol Appl Neurobiol; 1999 Oct; 25(5):400-7. PubMed ID: 10564530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of cell proliferation, epidermal growth factor receptor, and bcl-2 immunoexpression as prognostic factors for patients with World Health Organization grade 2 oligodendroglioma.
    Reis-Filho JS; Faoro LN; Carrilho C; Bleggi-Torres LF; Schmitt FC
    Cancer; 2000 Feb; 88(4):862-9. PubMed ID: 10679656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telomerase expression shows differences across multiple regions of oligodendroglioma versus high grade astrocytomas but shows correlation with Mib-1 labelling.
    Kleinschmidt-DeMasters BK; Hashizumi TL; Sze CI; Lillehei KO; Shroyer AL; Shroyer KR
    J Clin Pathol; 1998 Apr; 51(4):284-93. PubMed ID: 9659240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCNU down-regulates anti-apoptotic proteins bcl-xL and Bcl-2 in association with cell death in oligodendroglioma-derived cells.
    Lytle RA; Jiang Z; Zheng X; Rich KM
    J Neurooncol; 2004 Jul; 68(3):233-41. PubMed ID: 15332326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct radiochemotherapy protocols differentially influence cellular proliferation and expression of p53 and Bcl-2 in glioblastoma multiforme relapses in vivo.
    Deininger MH; Grote E; Wickboldt J; Meyermann R
    J Neurooncol; 2000 Jun; 48(2):121-9. PubMed ID: 11083075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of apoptosis in the prognosis of oligodendrogliomas.
    Schiffer D; Dutto A; Cavalla P; Chiò A; Migheli A; Piva R
    Neurochem Int; 1997 Aug; 31(2):245-50. PubMed ID: 9220457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-expression of mitosis-regulating genes contributes to malignant progression and prognosis in oligodendrogliomas.
    Liu Y; Hu H; Zhang C; Wang H; Zhang W; Wang Z; Li M; Zhang W; Zhou D; Jiang T
    Oncotarget; 2015 Nov; 6(35):38257-69. PubMed ID: 26468983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclooxygenase (COX)-1 expressing macrophages/microglial cells and COX-2 expressing astrocytes accumulate during oligodendroglioma progression.
    Deininger MH; Meyermann R; Trautmann K; Morgalla M; Duffner F; Grote EH; Wickboldt J; Schluesener HJ
    Brain Res; 2000 Dec; 885(1):111-6. PubMed ID: 11121536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ki-67 and MCM6 labeling indices are correlated with overall survival in anaplastic oligodendroglioma, IDH1-mutant and 1p/19q-codeleted: a multicenter study from the French POLA network.
    Pouget C; Hergalant S; Lardenois E; Lacomme S; Houlgatte R; Carpentier C; Dehais C; Rech F; Taillandier L; Sanson M; Appay R; Colin C; Figarella-Branger D; Battaglia-Hsu SF; Gauchotte G
    Brain Pathol; 2020 May; 30(3):465-478. PubMed ID: 31561286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular endothelial growth factor expression in oligodendrogliomas: a correlative study with Sainte-Anne malignancy grade, growth fraction and patient survival.
    Varlet P; Guillamo JS; Nataf F; Koziak M; Beuvon F; Daumas-Duport C
    Neuropathol Appl Neurobiol; 2000 Aug; 26(4):379-89. PubMed ID: 10931372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of cyclin A and topoisomerase IIalpha of oligodendrogliomas is correlated with tumour grade, MIB-1 labelling index and survival.
    Park SH; Suh YL
    Histopathology; 2003 Apr; 42(4):395-402. PubMed ID: 12653952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of 9p deletion and p16, Cyclin D1, and Myc hyperexpression on the outcome of anaplastic oligodendrogliomas.
    Michaud K; de Tayrac M; D'Astous M; Paquet C; Gould PV; Saikali S
    PLoS One; 2018; 13(2):e0193213. PubMed ID: 29489901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atypical bronchopulmonary carcinoids show a tendency toward increased apoptotic and proliferative activity.
    Laitinen KL; Soini Y; Mattila J; Pääkkö P
    Cancer; 2000 Apr; 88(7):1590-8. PubMed ID: 10738217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic significance of DNA topoisomerase II-alpha (Ki-S1), p21/Cip-1, and p27/Kip-1 protein immunoexpression in oligodendrogliomas.
    Korshunov A; Golanov A
    Arch Pathol Lab Med; 2001 Jul; 125(7):892-8. PubMed ID: 11419973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers.
    Krajewska M; Krajewski S; Epstein JI; Shabaik A; Sauvageot J; Song K; Kitada S; Reed JC
    Am J Pathol; 1996 May; 148(5):1567-76. PubMed ID: 8623925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic relevance of TP53 mutations, p53 protein, Ki-67 index and conventional histological grading in oligodendrogliomas.
    Hagel C; Krog B; Laas R; Stavrou DK
    J Exp Clin Cancer Res; 1999 Sep; 18(3):305-9. PubMed ID: 10606174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CDKN2/p16 predicts survival in oligodendrogliomas: comparison with astrocytomas.
    Miettinen H; Kononen J; Sallinen P; Alho H; Helen P; Helin H; Kalimo H; Paljärvi L; Isola J; Haapasalo H
    J Neurooncol; 1999 Feb; 41(3):205-11. PubMed ID: 10359140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nogo-A: a useful marker for the diagnosis of oligodendroglioma and for identifying 1p19q codeletion.
    Marucci G; Di Oto E; Farnedi A; Panzacchi R; Ligorio C; Foschini MP
    Hum Pathol; 2012 Mar; 43(3):374-80. PubMed ID: 21835431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcome of oligodendrogliomas.
    Lebrun C; Fontaine D; Ramaioli A; Vandenbos F; Chanalet S; Lonjon M; Michiels JF; Bourg V; Paquis P; Chatel M; Frenay M;
    Neurology; 2004 May; 62(10):1783-7. PubMed ID: 15159478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.